Tuesday November 24 2009 | Biotechnology feed | All feeds
|
|
|
ViroPharma
Download detailed PDF Members: At ViroPharma, we are dedicated to transforming the lives of patients through the commercialization of new and important medicines. Our goal is to focus on developing and marketing innovative products addressing unmet medical needs. We are continuing to position ourselves to do just that. We are a pharmaceutical company focused on the development and commercialization of important medicines to address serious diseases treated by physician specialists, in areas including hospital settings, transplant medicine and gastroenterology. Our marketed product, VANCOCIN® CAPSULES , is a potent oral antibiotic used by our target physician specialists, internists and gastroenterologists primarily in hospital settings, to treat two significant bacterial infections of the lower digestive tract: antibiotic-associated pseudomembranous colitis (PMC) and staphylococcal enterocolitis. Further, we are developing two promising core clinical opportunities, maribavir for prevention of cytomegalovirus infection, and our our hepatitis C compound, HCV-796. Finally, we have intranasal pleconaril, a financial value driver for ViroPharma now in the hands of Schering-Plough. We will use our current clinical product portfolio as our foundation for growth, supported by revenues from sales of Vancocin, and expand on our franchises in diseases treated by physician specialists in areas including hospital settings, transplant medicine and gastroenterology, by capitalizing on business execution and, as appropriate, prudent business development. Our goal is to become a profitable North American-based pharmaceutical company recognized worldwide for successfully developing and marketing drugs to meet the multiple needs of patients suffering from diseases that are not adequately treated by available therapies. The values on which we have built our business are important assets to us: Customer focus, quality, passion, continuous improvement, courage, teamwork and integrity. These values are evident throughout ViroPharma: the way we conduct our business, the way we communicate with our various customers, and in the manner in which we relate to one another. We are driven every day by a single human objective: to improve the lives of patients impacted by diseases with few treatment options. We have begun to do just that with Vancocin, an important medicine approved to treat two significant and debilitating lower digestive tract infections. We will continue toward that objective through our efforts to develop and commercialize additional important medicines. We will continue to invest in product and business development. We will maintain our focus on building shareholder value. We will maintain our focus on the needs of patients, physicians and payers. And, we will remain committed to quality and the continuous improvement of our performance, products and people. At ViroPharma, we are obsessed with bringing new and important medicines to market, and improving healthcare.
This page has been viewed 496 times since April 2007, the link to the organisation's website has been followed 87 times Recent Search Terms used to find this page: Assessing the economic merits of managing cytomegalovirus infection in organ and stem cell transplantation | viropharma patents | viropharma limited | ViroPharma Ltd | Viropharma U.S. locations | vphm pullback | viropharma influenza | . Search for more companies in Exton Search for more companies in PA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for ViroPharma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
